A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

被引：5

作者：

Advani, Ranjana ^{[1
]}

Lebmic, Daniel ^{[2
]}

Brunvand, Mark ^{[3
]}

Chen, Andy I. ^{[4
]}

Goy, Andre ^{[5
]}

Chang, Julie E. ^{[6
]}

Maeda, Lauren S. ^{[1
]}

Ho, William ^{[7
]}

Kahn, Robert ^{[7
]}

Lu, Dan ^{[7
]}

Su, Meng ^{[7
]}

Chu, Yu-Waye ^{[7
]}

Cheson, Bruce D. ^{[8
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Univ Michigan, Ann Arbor, MI 48109 USA

[3] Colorado Blood Canc Inst, Denver, CO USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[6] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Georgetown Univ Hosp, Washington, DC 20007 USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.59.59

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页数：2